라인 테라퓨틱스(RNTX)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.81 (+2.35%), 시가총액 $0.09B, 52주 범위 $0.97 ~ $2.05.
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF). It also offers LTI-01, a proenzyme that has completed Phase 1b and Phase 2a clinical trials in LPE patients for the treatment of loculated pleural effusion. The company's pipeline also includes preclinical programs targeting cystic fibrosis and a peptide program focused on the caveolin-1 protein for systemic fibrosis indications; and LTI-05, an epithelial sodium
라인 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
라인 테라퓨틱스의 현재 주가는 $0.81 (+2.35%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
라인 테라퓨틱스의 시가총액은 약 $0.09B입니다.
Rein Therapeutics Inc., a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lea